Whitehawk Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 11, 2025, details the results of Whitehawk Therapeutics, Inc.'s Annual Meeting of Stockholders held on that date. The company is incorporated in Delaware and trades on The Nasdaq Stock Market under the symbol WHWK.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes rather than financial performance.
Material Changes and Voting Results
Approximately 61% of the voting power (28,690,008 shares) was present at the meeting, constituting a quorum. The following material actions were taken:
- Board Composition Change: The authorized number of directors was decreased from ten (10) to nine (9), structured as three Class I, three Class II, and three Class III directorships.
- Director Elections (Proposal 1): Three Class II directors were elected to serve until the 2028 Annual Meeting. Voting results were as follows:
- Anupam Dalal, M.D.: 18,532,860 For; 5,029,089 Withheld.
- Mohammad Hirmand, M.D.: 19,402,347 For; 4,159,602 Withheld.
- David Lennon, Ph.D.: 19,378,308 For; 4,183,641 Withheld.
- Executive Compensation (Proposal 2): The advisory vote on executive compensation was approved with 18,855,748 votes For, 4,692,033 Against, and 14,168 Abstentions.
- Auditor Ratification (Proposal 3): The appointment of BDO USA, P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified with 28,065,323 votes For, 524,039 Against, and 100,646 Abstentions.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to reporting the outcomes of the shareholder vote.
Key Facts for Investor Verification
- Verify the reduction of the Board of Directors from 10 to 9 members and the implications for board governance.
- Confirm the re-election of the three Class II directors and their respective terms expiring in 2028.
- Note the significant number of Broker Non-Votes (5,128,059) recorded for all proposals, indicating shares held by brokers that were not voted on these matters.
- Review the definitive Proxy Statement filed on April 28, 2025, for detailed background on the executive compensation and director nominees.